Mainstream

Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025

Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025

Post Contentalur, alur.wsRead More

You might also be interested in reading Bitcoin’s Next Stop: $75,500? Analyst Reveals Historical ‘Magnet’ Level.

May 14, 2025
In Mainstream